Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Gastroenterology

Volumn 155, Issue 2, 2018, Pages 337-346.e10

  Kirchgesner, Julien ^a,b,c   Lemaitre, Magali ^a   Carrat, Fabrice ^b   Zureik, Mahmoud ^a,e   Carbonnel, Franck ^d   Dray Spira, Rosemary ^a  

^a Department of Epidemiology of Health Products   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Anti TNFs; Combination Therapy; Infection; Inflammatory Bowel Disease; Thiopurines

Indexed keywords

MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BACTERIAL INFECTION; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEMOGRAPHY; FEMALE; FRANCE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SOCIAL ASPECT; VIRUS INFECTION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85050487099     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.04.012     Document Type: Article

References (36)

1. Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
2. Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400.e3.
3. Gionchetti, P., Dignass, A., Danese, S., et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: surgical management and special situations. J Crohns Colitis, 2016, jjw169.
4. Harbord, M., Eliakim, R., Bettenworth, D., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11 (2017), 769–784.
5. Rahier, J.F., Magro, F., Abreu, C., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8 (2014), 443–468.
6. Beaugerie, L., Itzkowitz, S., Cancers complicating inflammatory bowel disease. N Engl J Med 372 (2015), 1441–1452.
7. Bonovas, S., Fiorino, G., Allocca, M., et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 14 (2016), 1385–1397.e10.
8. Nyboe Andersen, N., Pasternak, B., Friis-Møller, N., et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ, 350, 2015, h2809.
9. TM registry. Am J Gastroenterol 107 (2012), 1409–1422.
10. Grijalva, C.G., Chen, L., Delzell, E., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306 (2011), 2331–2339.
11. Lin, Z., Bai, Y., Zheng, P., Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol 23 (2011), 1100–1110.
12. Lichtenstein, G.R., Diamond, R.H., Wagner, C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 30 (2009), 210–226.
13. Osterman, M.T., Sandborn, W.J., Colombel, J.-F., et al. Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol 111 (2016), 1806–1815.
14. Osterman, M.T., Haynes, K., Delzell, E., et al. Effectiveness and safety of immunomodulators with anti–tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 1293–1301.e5.
15. Tuppin, P., Roquefeuil L de, Weill, A., et al. French national health insurance information system and the permanent beneficiaries sample. Rev DÉpidémiologie Santé Publique 58 (2010), 286–290.
16. Bouillon, K., Bertrand, M., Maura, G., et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2 (2015), e150–e159.
17. Raguideau, F., Lemaitre, M., Dray-Spira, R., et al. Association between oral fluoroquinolone use and retinal detachment. JAMA Ophthalmol, 134, 2016, 415.
18. Kirchgesner, J., Lemaitre, M., Rudnichi, A., et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther 45 (2017), 37–49.
19. Kirchgesner, J., Beaugerie, L., Carrat, F., et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut, 2017 gutjnl-2017-314015.
20. Lemaitre, M., Kirchgesner, J., Rudnichi, A., et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318 (2017), 1679–1686.
21. Annese, V., Beaugerie, L., Egan, L., et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9 (2015), 945–965.
22. Legifrance. Code de la santé publique—Article R5123-2. http://www.legifrance.gouv.fr. Accessed January 15, 2017.
23. Sahli, L., Lapeyre-Mestre, M., Derumeaux, H., et al. Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. Pharmacoepidemiol Drug Saf 25 (2016), 785–789.
24. Robins, J.M., Hernan, M.A., Brumback, B., Marginal structural models and causal inference in epidemiology. Epidemiology 11 (2000), 550–560.
25. Cole, S.R., Hernán, M.A., Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168 (2008), 656–664.
26. Toruner, M., Loftus, E.V., Harmsen, W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008), 929–936.
27. Baddley, J.W., Winthrop, K.L., Chen, L., et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis 73 (2014), 1942–1948.
28. Salmon-Ceron, D., Tubach, F., Lortholary, O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70 (2011), 616–623.
29. Dixon, W.G., Watson, K., Lunt, M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006), 2368–2376.
30. Curtis, J.R., Patkar, N., Xie, A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 56 (2007), 1125–1133.
31. Lorenzetti, R., Zullo, A., Ridola, L., et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 46 (2014), 547–554.
32. Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases. with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42.
33. Robins, J.M., Hernan, M.A., Brumback, B., Marginal structural models and causal inference in epidemiology. Epidemiology 11 (2000), 550–560.
34. Cole, S.R., Hernán, M.A., Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168 (2008), 656–664.
35. Hernán, M.Á., Brumback, B., Robins, J.M., Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11 (2000), 561–570.
36. Nyboe Andersen, N., Pasternak, B., Friis-Møller, N., et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ, 350, 2015, h2809.